Abstract
Retifanlimab (retifanlimab-dlwr; -ZYNYZ(TM)) is a programmed cell death 1 receptor-blocking antibody that is being developed by Incyte Corporation for......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
